DRKS00026768招募中未知
Re-Source Phase II: Strengthening health resources among teachers. - Re-Source II
Institut und Poliklinik für Arbeits-, Sozial- und Umweltmedizin der Friedrich-Alexander Universität Erlangen-Nürnberg0 个研究点目标入组 70 人开始时间: 2021年10月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- one 至 one（—）
- 性别
- All
入选标准
- •Teachers who are currently in active school service and do not have any manifest mental illnesses are included in the survey in phases I and II.
- •Therapists who carry out the intervention in Bad Brückenau are the target group for phase II.
排除标准
- •Student teachers and retired/retired teachers and teachers with manifest, mental illnesses.
研究者
相似试验
进行中（未招募）
2 期
PF-07104091 as a Single Agent and in Combination TherapyAdvanced or metastatic breast cancer and other solid tumorJPRN-jRCT2031220134Kawai Norisuke320
进行中（未招募）
1 期
Extending the treatment of Iron OverloadPatients with transfusional iron overload due to hereditary anemias such as sickle cell disease, beta-thalassemia and Diamond-Blackfan anemiaaquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure.MedDRA version: 16.1Level: LLTClassification code 10065974Term: Chronic iron overloadSystem Organ Class: 100000004861EUCTR2011-006322-25-GBShire Development LLC1,500
已完成
2 期
BYLIEVE: A phase II, multicenter, open-label, three-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatmentsbreast CancerNL-OMON52978ovartis6
进行中（未招募）
不适用
A Phase 2 multi-center, open label, long-term extension trial to assess the safety of oral UK-390,957 administered as required in adult men with premature ejaculation - N/AMedDRA version: 7.1Level: LLTClassification code 10036596Premature EjaculationEUCTR2004-003737-13-GBPfizer Limited1,058
进行中（未招募）
不适用
A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation. - N/AMedDRA version: 7.0Level: LLTClassification code 10036596Premature EjaculationEUCTR2004-003737-13-ATPfizer Corporation Austria Ges.m.b.H., Clinical Research1,058